Retatrutide and Tirzepatide from ₱750 a vial in 25, 50 and 100 packs. Split it with friends or resell it under your own label.From ₱750 a vial: 25, 50 and 100 packs for group buys and resellers. See bulk prices →

Weight loss · Compound

Cagrilintide

Long-acting amylin analogue studied for obesity, alone and in combination with semaglutide.

Philippines Peptides editorial deskUpdated Trial data checked 23 September 20264 min read

Cagrilintide is not yet in the evidence datasets this site draws on, so this page makes no claim about what it does.

What is Cagrilintide

Cagrilintide is a long-acting analogue of amylin, a peptide hormone released with insulin by pancreatic beta cells after meals. Amylin is involved in satiety signalling and slows gastric emptying. Cagrilintide is covered in the weight loss peptide section of this site.

Developed by Novo Nordisk, cagrilintide is being studied alone and in combination with semaglutide, a combination known as CagriSema. This page cites no primary trial source, and cagrilintide is not in the evidence datasets this site draws on, so no trial result or figure is shown here.

Cagrilintide acts on amylin receptors. GLP-1 medicines such as semaglutide and tirzepatide act on GLP-1 receptors, a different pathway.

How it works

Amylin receptors: cagrilintide is designed to activate amylin receptors, including those in the area postrema and nucleus tractus solitarius of the brainstem, regions involved in satiety signalling. This mechanism is based on amylin physiology; this page cites no study that measured it for cagrilintide.

Gastric emptying: amylin slows the rate at which food leaves the stomach. Cagrilintide, as an amylin analogue, is designed to reproduce this effect.

Glucagon: amylin suppresses glucagon release after meals. Cagrilintide is designed to act the same way.

Benefits studied

Cagrilintide is not yet in the evidence datasets this site draws on, so this page makes no claim about what it does. Anything published about it elsewhere should be read with its evidence level in mind: most peptides in this category have animal or cell data only.

Side effects reported

No controlled human data on adverse events for Cagrilintide is in the datasets this site draws on, so its safety in people is unknown rather than established. Effects commonly described for it are listed below; how often they occur has not been measured in a controlled trial.

  • Nausea
  • Decreased appetite
  • Vomiting
  • Diarrhea or constipation
  • Injection site reactions
  • Hypoglycemia
  • Pancreatitis (theoretical)
  • Gallbladder problems

Regulatory status

The regulatory dataset this site draws on has no row for Cagrilintide.

Who should not use Cagrilintide

FAQ

How does cagrilintide differ from GLP-1 medicines?

Cagrilintide is an amylin analogue and acts on amylin receptors. GLP-1 medicines such as semaglutide act on GLP-1 receptors. CagriSema is the name for cagrilintide combined with semaglutide.

What evidence exists for cagrilintide?

Cagrilintide is being studied alone and in combination with semaglutide. This page cites no primary trial source, and cagrilintide is not in the evidence datasets this site draws on, so no benefit or trial figure is shown here.

Is cagrilintide approved in the Philippines?

The regulatory dataset this site draws on has no row for cagrilintide, so this page makes no claim about its approval status. The regulatory status page lists the compounds that dataset covers.

Where to get Cagrilintide in the Philippines

Primara Labs, our partner and supplier, lists their current vials on the catalogue. Prices and stock change, so check there for what is available now. View the Primara Labs catalogue

The supply index covers what to ask a seller before paying, and why quoted prices vary so widely.

View Supply Index

Risk · Disclosure · Editorial Status

This page is editorial information for adults researching peptide therapy. It is not medical advice, not a prescription, and not an endorsement of any specific product, supplier, or protocol. Side effects can be serious and individual response varies. Talk to a licensed physician (ideally one with peptide-specific clinical experience) before starting any compound, adjusting a dose, or discontinuing therapy.

In the Philippines, GLP-1 medications are prescription-only under FDA Philippines regulation. Research-grade peptides occupy a regulatory gray area: import for personal research use is generally tolerated, but the Bureau of Customs reserves the right to inspect and detain shipments. Do not import for resale.

Editorial Status
Non-clinical
Affiliation
Not a clinic · Not a pharmacy
Last Updated
September 24, 2026

Related peptides

Updated